Shares in Eco Animal Health Group Plc (AIM:EAH) rose 10% on Monday after the company reassured investors that global trade tariffs have not materially impacted its business.
ECO reported revenue of £79.6 million for the year ended March 2025, in line with expectations, with strong growth in North America, where sales increased 16%.
The group’s gross margin improved to 45%, supported by cost control and favourable geographic mix, while adjusted EBITDA stood at £7.3 million.
It said it continues to invest in its research and development pipeline, including the recent submission of a poultry vaccine dossier to the European Medicines Agency, targeting a 2026 launch.
CEO David Hallas highlighted robust sales of the flagship product Aivlosin and ongoing progress despite challenging market conditions.
ECO also completed disposals of non-core assets to focus resources on core areas and has launched a share buy-back scheme to support employee incentives.
The company remains cautious but optimistic about navigating geopolitical uncertainties and tariff impacts.
The shares rose 5.75p to 62.75p.